Dear stakeholders,

I would like to begin by expressing my sincere gratitude for your continued support for and understanding of the Daiichi Sankyo group of companies (the Daiichi Sankyo Group) and its business.

Our mission is to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals and through the provision of pharmaceuticals addressing diverse medical needs. Contributing to the enrichment of quality of life around the world is definitely the purpose (or significance) of the Daiichi Sankyo Group in society. 

Our Mission

Daiichi Sankyo Company, Limited (the Company) began its journey by extracting adrenaline, discovering orizanin (vitamin B), and producing salvarsan (antimicrobial agent treatment for syphilis) in Japan, with the goal of becoming a drug discovery-oriented company with Japanese origins. Since then, the Company has continuously met many of the unmet medical needs of the era by creating innovative drugs, including drugs treatment for lifestyle-related diseases such as hyperlipidemia and high blood pressure, and antibiotics, and delivering them to patients across the world. In 2020, we launched an anti HER2 antibody drug conjugate (ADC) in the United States (in January) and Japan (in May) to provide third-line treatment to patients with HER2 positive metastatic breast cancer and started contribution to these patients. By delivering the 3 ADCs of an anti HER2-ADC as well as subsequent products an anti TROP2-ADC and an anti HER3-ADC to as many patients as early as possible, we aim to realize our 2025 Vision of becoming a “Global Pharma Innovator with competitive advantage in oncology.”

2025 Vision

It takes ten to twenty years from the start of research to the launch of a pharmaceutical product. In the case of anti HER2-ADC, it took over ten years to deliver this product to patients. Adopting a mid- to long-term perspective, the Daiichi Sankyo Group will continue to address both current and future unmet medical needs by continuously creating innovative post-ADC pharmaceutical products using new modalities and technologies, including genetic therapies, nucleic-acid drugs, and cell therapies. 
Our R&D Strategy & Operations

Moreover, we have identified key issues (materialities) related to our business which express stakeholder and societal expectations of the Daiichi Sankyo Group’s activities and their significance in terms of reflecting their impact on mid-to-long-term corporate-value enhancement. These materialities include the creation of innovative pharmaceuticals as well as materialities related to our operating foundation, such as the need to strengthen corporate governance and promote environmental management. 


In addition, we are now creating the next 5-year business plan, which covers the next five fiscal years (2021 to 2025). In March or April 2021, we will present the steps that must be taken in the next period to achieve the 2025 Vision, along with future actions beyond 2025. 

The coronavirus disease (COVID-19) is now widespread across the world. To fulfill the mission of a pharmaceutical company, we are maintaining a stable supply of drugs, as well continuing our work to research and develop innovative pharmaceutical products. At the same time, we are making efforts to control the spread of COVID-19 among our employees and other persons, while reducing the burden on medical facilities. As a group of companies with many scientific and technological advantages and an existing vaccine-business infrastructure, we are currently conducting research and aiming to develop a COVID-19 vaccine alongside other COVID-19 treatments urgently needed by society. We have also increased our production of influenza vaccines in response to increasing concerns about simultaneous COVID-19 and seasonal-influenza pandemics.
Our Company’s Efforts to Limit the Spread of the Virus that Causes COVID-19

The Daiichi Sankyo Group’s greatest strengths are the creation of new drugs through full use of leading-edge science and technology and the human resources that support it. We continue to be fully committed to realizing our corporate mission by leveraging these collective strengths to contribute to patients' health, society, and a better future for everyone.
Our Strengths

I hope that this website will help our stakeholders better and more deeply understand the work we are doing to resolve social issues, as well as the value we aim to deliver to society. 


Sunao Manabe  
Representative Director  
President and CEO  
眞鍋 淳